Updated Recommendations on INSTI-Based Regimens for ART-Naive Patients

All three licensed HIV integrase inhibitors are now listed as preferred antiretroviral agents for initial treatment of HIV-infected individuals.

Sponsoring Organization: Department of Health and Human Services (DHHS)

Target Population: Healthcare providers who prescribe antiretroviral therapy (ART) for HIV-infected patients

Background and Objective

Based on data from recently published and presented clinical trials, the DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents updated its recommendations for initial ART to include all three currently licensed HIV integrase strand transfer inhibitors (INSTIs), in combination with tenofovir/FTC or abacavir/3TC, as components of preferred regimens.

Key Recommendations

The DHHS Antiretroviral Treatment Guidelines include recommendations for initial treatment of HIV infection with preferred and alternative combination regimens. Previ…

Reviewing Author

Charles B. Hicks, MD

Disclosures

Consultant / Advisory boardGilead Sciences; ViiV; Merck

RoyaltiesUpToDate, Inc.

Grant / Research supportNIH; Department of Health and Human Services